|
|
||||||||
Articles |
1
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
2
Department of Pathology, Princess Margaret Hospital, Hong Kong, China
Departments of
3
Medicine and
4
Pathology, Queen Elizabeth Hospital, Hong Kong, China
a author for correspondence: fax 852-2636-5090, e-mail
ching-wanlam{at}cuhk.edu.hk
| Introduction |
|---|
|
|
|---|
The human HMBS gene spans
10 kb of DNA on chromosome
11q24.1-24.2 and contains 15 exons (4). Extensive allelic
heterogeneity has been demonstrated in this gene, and 159 mutations
have been identified in the HMBS gene (5). Most
of these mutations are found only in individual families, except those
found in Dutch (R116W) (6) and Swedish (W198X)
(7) AIP families. Although DNA sequencing can identify all
the mutations, this approach is both labor-intensive and time-consuming
(8). Several methods that accelerate mutational screening
before sequencing have been developed, such as single-strand
conformation polymorphism analysis (9), heteroduplex gel
analysis (10), and denaturing gradient gel
electrophoresis (11)(12). Recently, denaturing
HPLC (DHPLC) appears to be more sensitive than other methods in
mutation detection, as exemplified in the detection of TSC1
(13), TSC2 (14), BRCA1
(15)(16), BRCA2 (15),
CFTR (13), EXT1 (17),
EXT2 (17), and HPRT (18).
Here, we describe the use of DHPLC for mutation scanning in a family
with AIP.
The patient was a 40-year-old woman presenting with frequent acute episodes of abdominal pain and convulsions. In one episode of acute attack, urine porphobilinogen was 117 µmol/mmol of creatinine (reference limit <10 µmol/mmol of creatinine). Reversed-phase high-performance thin-layer chromatography showed a normal pattern of fecal porphyrin excretion (19)(20). The patient was diagnosed to have AIP, but the RBC HMBS activity, measured at a time when she was anemic, was within the reference interval (35 nmol/mL of RBC per hour; reference interval, 2866 nmol/mL of RBC per hour). The RBC HMBS activity of the mother was low (27.5 nmol/mL of RBC per hour), whereas the father had normal activity (52.4 nmol/mL of RBC per hour). On the basis of these data, the mother was an asymptomatic carrier and the patient was a manifesting individual of AIP.
Genomic DNA was extracted from whole-blood samples of the patient and the family members by a commercially available method (QIAamp; Qiagen). The study was performed in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all subjects. All of the exons and the flanking introns of the HMBS gene were amplified using previously described primers (21). Exon 15 of the HMBS gene was amplified into two fragments [i.e., exon 15A (nucleotide positions 90519469) and exon 15B (nucleotide positions 93739700)]. Heteroduplex analysis was performed on a WAVETM DHPLC instrument (Transgenomic Inc.). Analysis on the system was performed at a temperature sufficient to partially denature (melt) the DNA heteroduplexes. The partially denatured heteroduplexes were resolved from the corresponding homoduplexes by ion-pair reversed-phase HPLC (22). The stationary phase consisted of 2-µm nonporous alkylated poly(styrene-divinylbenzene) particles packed into a 50 x 4.6 mm (i.d.) column (DNASep column; Transgenomic Inc.). Crude PCR product (10 µL) was loaded on the column and eluted from the column by an acetonitrile gradient in 0.1 mol/L triethylammonium acetate (TEAA; pH 7.0) buffer at a constant flow rate of 0.9 mL/min. The buffers were prepared from TEAA buffer concentrate to give the following: buffer A, 0.1 mol/L TEAA; buffer B, 0.1 mol/L TEAA containing 250 mL/L acetonitrile. The gradient was created by mixing buffers A and B. The recommended gradient for mutation detection was a slope of 2% increase in buffer B per minute. Eluted DNA fragments were detected with ultraviolet absorbance at a wavelength of 260 nm. The WAVE utility software helped determine the correct temperature for mutation scanning based on the sequence of the wild-type DNA. This approach was modified during the analysis of DNA from individuals carrying two identical mutant alleles (homozygous mutation). The PCR product spanning the homozygous mutation was mixed with equal amounts of wild-type amplified DNA and hybridized. After this treatment, a sample contained a mixture of hetero- and homoduplexes.
PCR products were purified by Microspin S300 columns (Amersham Pharmacia), and both strands were sequenced using the amplification primers as sequencing primers and BigDyeDeoxyTM terminator cycle sequencing reagents according to the manufacturers instructions (PE Biosystems). Products of sequencing reactions were purified by Centri-SepTM spin columns (Princeton Separations). Purified sequencing fragments were separated by capillary electrophoresis and detected via laser-induced fluorescence on an ABI PRISM 310 Genetic Analyzer (PE Biosystems). Sequencing results were compared with the established human HMBS sequence (GenBank Accession No. M95623).
For the proband (II2), the DHPLC chromatograms of exons 11 (Fig. 1A
), 14, 15A, and 15B (data not shown) showed the presence of
heteroduplex peaks. Direct DNA sequencing of exon 11 showed a double
heterozygous pattern (data not shown). The mutation is a one-nucleotide
deletion, 8193delC. This mutation alters the reading frame of the
encoded protein such that a stop codon, TGA, is generated at codon 254
(i.e., L254X). The predicted mutant HMBS is a truncated protein of 253
amino acids, compared with 361 residues for the wild-type protein.
Screening of the family members by DHPLC and subsequent sequencing
confirmed that only the mother (I2) had a 8193delC mutation. This
8193delC mutation was not detected in 50 apparently healthy
Chinese individuals. This is the first disease-causing mutation
identified in the HMBS gene in Chinese individuals. Direct
sequencing of both exon 14 and exon 15A and the flanking introns of the
proband showed a novel transition in intron 14, at position 9103,
changing the base from guanine to adenine, i.e., 9103G
A (Fig. 1B
).
The size of intron 14 was only 88 bp, and the two PCR products both
contained the nucleotide at 9103. When we analyzed 50 apparently
healthy Chinese individuals, we found that 49 were 9103G/G and 1 was
9103G/A. The allele frequency of 9103G thus was 0.99, and that of 9103A
was 0.01. Direct sequencing of exon 15B and the flanking introns showed
our previously described single nucleotide polymorphism (SNP),
9678G
A (23).
|
Interestingly, DHPLC chromatograms of exon 11 of the other family
members (III1, III2, and III3) also showed the presence of heteroduplex
peaks. However, the elution profiles were different from that of
8193delC (Fig. 1A
). Direct sequencing of the PCR products showed a
transversion in intron 10, at position 8164, changing the base from
cytosine to adenine, i.e., 8164C
A (data not shown). The 8164C
A
transversion is not present in the patient or her mother, thus
confirming that 8164C
A is a neutral polymorphism. When we analyzed
50 apparently healthy Chinese individuals, we found that 11 were
8164A/A, 28 were 8164A/C, and 11 were 8164C/C. The allele frequency of
8164A thus is 0.50, and that of 8164C is 0.50. Using the three genomic
SNPs, we constructed complete haplotypes for all family members. The
haplotypes for the chromosome carrying the disease-causing
mutation are 8164C, 9103G, and 9678G. Thus, only the mother and the
proband are carriers, and the other family members do not have the
mutant alleles (Fig. 1B
). The results of haplotype analysis are
consistent with the results of mutation detection.
DNA-based diagnosis of AIP was particularly useful in the proband as RBC HMBS activity is uninterpretable in the presence of hemolysis. In this study, we used DHPLC to identify a novel HMBS mutation that causes AIP, and together with the three SNPs, we have determined the haplotypes for the mutation. The haplotypes are informative for this family. We can use either direct mutation detection or linkage analysis to determine whether other family members carry the AIP chromosome.
DHPLC has several advantages over other mutation detection methods. DHPLC is fully automated, eliminating the time and labor in gel preparation, loading, analyzing, and photographic documentation. The PCR products are loaded directly from a 96-well plate without any prior purification. Heteroduplex DNA is resolved from homoduplex DNA in a matter of minutes. The technology detects single-base changes as efficiently as short deletions and insertions. Heteroduplex peaks elute earlier than homoduplexes and can be observed as separate peaks or as shoulders on the leading edge of homoduplex peaks (22). Elution characteristics of the heteroduplex peaks are influenced by the specific base mismatch present and the melting characteristics of the surrounding bases. As demonstrated in this study, even mutations and SNPs located in the same PCR fragment can be distinguished by the characteristic elution profiles.
Although single-base mutations have been detected in 1.5-kb fragments
by DHPLC (24), PCR product <100 bp containing a mutant
allele with the C
G transversion cannot be resolved from the
wild-type allele (25). To achieve the highest accuracy, it
is better to amplify large exons into 150- to 450-bp fragments. In
addition, cases of possible homozygous mutations require premixing of
subject DNA with wild-type DNA. This is, however, less of a problem in
autosomal dominant diseases. Although an initial capital investment in
the HPLC instrument is required, the combination of low running costs
and the tremendous reduction in the effort of sequencing make the DHPLC
technique a suitable method for mutation detection
(26)(27).
| References |
|---|
|
|
|---|
A) for linkage analysis of acute intermittent porphyria. Clin Chem 1999;45:308-309.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |